JP2024526742A5 - - Google Patents

Info

Publication number
JP2024526742A5
JP2024526742A5 JP2024501754A JP2024501754A JP2024526742A5 JP 2024526742 A5 JP2024526742 A5 JP 2024526742A5 JP 2024501754 A JP2024501754 A JP 2024501754A JP 2024501754 A JP2024501754 A JP 2024501754A JP 2024526742 A5 JP2024526742 A5 JP 2024526742A5
Authority
JP
Japan
Prior art keywords
patient
weeks
composition according
ravulizumab
score
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2024501754A
Other languages
English (en)
Japanese (ja)
Other versions
JP2024526742A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2022/037147 external-priority patent/WO2023287991A1/en
Publication of JP2024526742A publication Critical patent/JP2024526742A/ja
Publication of JP2024526742A5 publication Critical patent/JP2024526742A5/ja
Pending legal-status Critical Current

Links

JP2024501754A 2021-07-14 2022-07-14 重症筋無力症の治療のための抗ｃ５抗体の投与量及び投与 Pending JP2024526742A (ja)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US202163221826P 2021-07-14 2021-07-14
US63/221,826 2021-07-14
US202163276271P 2021-11-05 2021-11-05
US63/276,271 2021-11-05
PCT/US2022/037147 WO2023287991A1 (en) 2021-07-14 2022-07-14 Dosage and administration of anti-c5 antibodies for treatment of myasthenia gravis

Publications (2)

Publication Number Publication Date
JP2024526742A JP2024526742A (ja) 2024-07-19
JP2024526742A5 true JP2024526742A5 (cg-RX-API-DMAC7.html) 2025-07-23

Family

ID=83004487

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2024501754A Pending JP2024526742A (ja) 2021-07-14 2022-07-14 重症筋無力症の治療のための抗ｃ５抗体の投与量及び投与

Country Status (4)

Country Link
US (1) US20250154232A1 (cg-RX-API-DMAC7.html)
EP (1) EP4370547A1 (cg-RX-API-DMAC7.html)
JP (1) JP2024526742A (cg-RX-API-DMAC7.html)
WO (1) WO2023287991A1 (cg-RX-API-DMAC7.html)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA3024618A1 (en) 2016-05-27 2017-11-30 Alexion Pharmaceuticals, Inc. Methods for treatment of refractory generalized myasthenia gravis

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8367805B2 (en) 2004-11-12 2013-02-05 Xencor, Inc. Fc variants with altered binding to FcRn
PY09026846A (es) 2008-08-05 2015-09-01 Novartis Ag Composiciones y métodos para anticuerpos que se dirigen a la proteína de complemento c5
NZ631007A (en) 2014-03-07 2015-10-30 Alexion Pharma Inc Anti-c5 antibodies having improved pharmacokinetics
BR112017011235A2 (pt) 2014-12-19 2018-02-06 Chugai Pharmaceutical Co Ltd anticorpos anti-c5 e métodos de uso
CN116769024A (zh) 2016-06-14 2023-09-19 瑞泽恩制药公司 抗c5抗体及其用途
EP3924380A1 (en) * 2019-02-14 2021-12-22 Alexion Pharmaceuticals, Inc. Dosage and administration of anti-c5 antibodies for treatment of generalized myasthenia gravis

Similar Documents

Publication Publication Date Title
JP2011506483A5 (cg-RX-API-DMAC7.html)
JP2014533279A5 (cg-RX-API-DMAC7.html)
JP7160533B2 (ja) 多発性骨髄腫（ｍｍ）の処置
JP2018511609A5 (cg-RX-API-DMAC7.html)
CN105263520A (zh) 包含抗cd38抗体和来那度胺的组合物
JP6184952B2 (ja) 抗ｃｄ１９抗体とナイトロゲンマスタードとの併用療法
RU2014117510A (ru) Лечение ревматоидного артрита
JP2024534602A5 (cg-RX-API-DMAC7.html)
JP2014534956A5 (cg-RX-API-DMAC7.html)
JP2014525926A5 (cg-RX-API-DMAC7.html)
JP2020504717A5 (cg-RX-API-DMAC7.html)
AU2018276384B2 (en) Treatment paradigm for an anti-CD19 antibody and venetoclax combination treatment
US20250075007A1 (en) Treatment of Al Amyloidosis with the Combination of Monoclonal Antibodies Agains Immunoglobulin Light Chains and the CD38 Cell Membrane Molecule on Antibody-Producing And Other Immune Cells
KR20240151809A (ko) Fcrn 길항제를 사용하여 근염을 치료하는 방법
JP2023520771A5 (cg-RX-API-DMAC7.html)
JP6560808B2 (ja) 抗（＋）メタンフェタミンモノクローナル抗体
JP2022520107A5 (cg-RX-API-DMAC7.html)
JP2023546503A5 (cg-RX-API-DMAC7.html)
JP2024526742A5 (cg-RX-API-DMAC7.html)
TW202321303A (zh) 抗pla2r自體抗體媒介膜性腎病變之治療
JP2024540435A5 (cg-RX-API-DMAC7.html)
JP2024521105A5 (cg-RX-API-DMAC7.html)
JP2023506779A5 (cg-RX-API-DMAC7.html)
JP2023504209A5 (cg-RX-API-DMAC7.html)
JP2025526402A5 (cg-RX-API-DMAC7.html)